Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study

Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial

(2012) H. Ralph Schumacher et al.   ARTHRITIS AND RHEUMATISM

Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout

(2011) Robert T. Keenan et al.   AMERICAN JOURNAL OF MEDICINE

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

(2011) Robert L. Wortmann et al.   CLINICAL THERAPEUTICS

Gout. Epidemiology of gout

(2011) Edward Roddy et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin-1 antagonism in acute gout: Is targeting a single cytokine the answer?

(2010) Tuhina Neogi   ARTHRITIS AND RHEUMATISM

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

(2010) Alexander So et al.   ARTHRITIS AND RHEUMATISM

Health Care Utilization in Patients with Gout

(2010) Jasvinder A. Singh et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis

(2009) R Torres et al.   ANNALS OF THE RHEUMATIC DISEASES

Toward a valid definition of gout flare: Results of consensus exercises using delphi methodology and cognitive mapping

(2009) W. J. Taylor et al.   ARTHRITIS AND RHEUMATISM

Case of anakinra as a steroid-sparing agent for gout inflammation

(2009) Sarah B. Gratton et al.   ARTHRITIS AND RHEUMATISM

Caspase 1–independent activation of interleukin-1β in neutrophil-predominant inflammation

(2009) Monica Guma et al.   ARTHRITIS AND RHEUMATISM

Inflammatory arthritis in caspase 1 gene–deficient mice: Contribution of proteinase 3 to caspase 1–independent production of bioactive interleukin-1β

(2009) Leo A. B. Joosten et al.   ARTHRITIS AND RHEUMATISM

The practical management of gout

(2009) H. R. SCHUMACHER et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

The role of hyperuricemia in vascular disorders

(2009) N Lawrence Edwards   CURRENT OPINION IN RHEUMATOLOGY

IL-1 Inhibition With Anakinra in a Patient With Refractory Gout

(2009) Dushyant Singh et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Safety and Pharmacokinetics of Subcutaneously Administered Rilonacept in Patients With Well-Controlled End-Stage Renal Disease (ESRD)

(2009) Allen Radin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM

Adherence with urate-lowering therapies for the treatment of gout

(2009) Leslie R Harrold et al.   ARTHRITIS RESEARCH & THERAPY

Differential requirement for the activation of the inflammasome for processing and release of IL-1  in monocytes and macrophages

(2008) M. G. Netea et al.   BLOOD

Gout

(2008) Lan X. Chen et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Uric Acid and Cardiovascular Risk

(2008) Daniel I. Feig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions

(2008) Becky A Briesacher et al.   PHARMACOTHERAPY